In 2015, three antibody-drug conjugates had received regulatory approval. By 2024, that number had grown to 15 — with over 260 additional candidates in active clinical trials. The global ADC market reached $7.6 billion in 2022 and is projected to exceed $28.6 billion by 2033. Behind this growth sits an increasingly complex intellectual property landscape that spans two disciplines rarely combined in a single molecule: biological engineering and synthetic organic chemistry.
A landmark review published in Nature Biotechnology in May 2026 — a decade after the field's first IP survey — provides a comprehensive update on global ADC patent strategy, prosecution trends, and litigation outcomes. This article unpacks the key findings for antibody development teams navigating the ADC space.
The Three-Component Patent Architecture of ADC Molecules
Every ADC is built on three independently patentable components: Antibody (A) — Linker (L) — Toxin (T). This architecture has a critical implication for IP strategy: novelty in any single component is sufficient to support patent claims on the entire conjugate molecule. Conversely, freedom-to-operate (FTO) risk exists at each of three independent layers simultaneously.
| Innovation Source | Claim Scope Achievable | Example |
|---|---|---|
| Novel target / antibody | Broad — covers all linker-toxin combinations | First anti-HER2 ADC claims |
| Novel toxin class | Intermediate — covers all antibody-linker combinations | Maytansinoid or pyrrolobenzodiazepine (PBD) payload claims |
| Novel single toxin | Intermediate — specific payload with any Ab or linker | DXd payload (Enhertu) |
| Novel linker technology | Broad platform — covers all antibody-toxin combinations using that linker | Synaffix's HydraSpace linker platform |
| Novel combination only | Narrow — specific A-L-T combination | Late-stage ADC with known components in new combination |
Understanding this matrix is the starting point for any ADC patent strategy. Teams that optimize only for the molecule's clinical profile — without mapping their innovation to a specific patent claim category — routinely find their IP portfolios thinner than expected at commercialization.
Antibody Component: How Claim Strategy Varies by Jurisdiction
Structure-Based vs. Target/Epitope-Based Claims
Antibody patents in ADC molecules follow two primary claim architectures:
- Structure-based claims — defined by CDR sequences, VH/VL domain sequences, or full heavy/light chain sequences. This is the universally accepted format across the USPTO, EPO, and CNIPA.
- Target/epitope-based claims — defined by what the antibody binds, not its structure (e.g., "an antibody that binds to epitope X on HER2"). Accepted in Europe under specific conditions; rejected by the USPTO and CNIPA as lacking adequate structural definition.
US vs. European Examination Standards
The examination standard gap between the USPTO and EPO is practically significant. The USPTO applies a structural non-obviousness test — a novel antibody sequence that was not previously disclosed is generally patentable without requiring proof of functional superiority. The EPO applies the problem-and-solution approach: if the target is already known and antibodies against it have been made, generating another antibody to the same target is considered routine unless experimental data demonstrate uniquely superior properties (binding kinetics, epitope selectivity, thermostability).
Practical implication: ADC developers should plan European antibody patent prosecution with functional characterization data from day one — SPR kinetics, epitope binning, and comparative assay performance data against known prior-art antibodies to the same target.
Linker Technology: The Most Defensible Platform IP Position
Among the three ADC components, linker technology generates the broadest and most commercially durable patent positions. A novel conjugation chemistry — one that controls DAR distribution, improves aqueous stability, or enables site-specific attachment — can be claimed broadly across all antibody-toxin combinations that use it, creating a platform IP position that supports large-scale licensing revenue independent of any specific product.
Conjugation Sites and DAR Control
IgG1 antibodies contain 32 cysteines — all engaged in disulfide bonds — and approximately 80 lysines, of which ~40 are surface-accessible for conjugation. Each conjugation approach carries distinct patent implications:
- Lysine conjugation — random modification producing heterogeneous DAR (0–8+); well-established art, limited patentability for new lysine-based conjugation claims
- Cysteine conjugation via interchain disulfide reduction — partially reduces structural disulfides; produces DAR 2–8 with moderate heterogeneity; early-stage IP now largely expired or expiring
- Thio-MAb (engineered cysteine) — introduces a free cysteine at a defined position by site-directed mutagenesis; achieves homogeneous DAR 2 with site-specific precision; core patents held by Genentech, filing priority from 2004–2008
- Enzymatic conjugation — sortase A, transglutaminase (with N297Q mutation), or formylglycine-generating enzyme (FGE) create defined, single-site attachment; rapidly expanding patent space with multiple filing parties from 2015–present
- Unnatural amino acid incorporation — amber suppression or genetic code expansion introduces reactive handles (azide, alkyne, tetrazine) at precisely defined positions; homogeneous DAR with flexibility in attachment chemistry; active IP development
Field observation: The most commercially active current IP territory in ADC linkers is enzymatic conjugation combined with hydrophilic spacer technologies. Daiichi Sankyo's collaboration with Synaffix (Lonza) on the HydraSpace platform — which adds polyethylene glycol-like spacers to suppress ADC hydrophobicity at high DAR — is representative of where novel linker IP is being built.
Toxin (Payload) IP: Class Claims vs. Single-Molecule Claims
ADC payloads must be potent enough to kill cancer cells at the quantities that internalization delivers — typically picomolar IC₅₀ values. Common payload classes and their IP status:
| Payload Class | Mechanism | IP Status (2026) |
|---|---|---|
| Maytansinoids (DM1, DM4) | Tubulin polymerization inhibitor | Core ImmunoGen patents largely expired; compound-specific claims remain |
| Auristatins (MMAE, MMAF) | Tubulin polymerization inhibitor | Seagen core patents expiring 2024–2027; active licensing market |
| Calicheamicins | DNA double-strand break | Pfizer/Wyeth patents; narrower scope, fewer competitors |
| PBDs (pyrrolobenzodiazepines) | DNA crosslinking | Spirogen/AZ platform; active patent protection |
| Camptothecin derivatives (DXd, SN-38) | Topoisomerase I inhibitor | Active patents; DXd core to Enhertu IP position |
| STING agonists, siRNA, radionuclides | Immune activation / gene silencing / radiation | Emerging; early-stage patent filings, broad claims available |
Payload hydrophobicity is both a clinical and IP consideration. Highly hydrophobic toxins released from cleavable linkers diffuse across cell membranes and kill adjacent cells — the "bystander effect" that is central to Enhertu's clinical differentiation. This membrane permeability can be claimed as a functional property that supports broader patent scope for the payload or the release mechanism.
Fc Engineering: ADCC Enhancement vs. Silencing
The Fc region of an ADC antibody mediates additional anti-tumor killing through ADCC, but also contributes to off-target toxicity and narrows the therapeutic window. Both enhancement and silencing have active patent landscapes:
- ADCC-enhancing mutations (S239D/I332E, G236A/S239D/I332E; afucosylation via FUT8 knockout) — increase FcγRIIIa binding affinity; core patents from Xencor, Roche, and AZ; used in combination with ADC payloads to achieve cooperative tumor killing
- ADCC-silencing mutations (L234A/L235A "LALA," L234A/L235A/P329G "LALA-PG," N297A/Q deglycosylation) — eliminate FcγR engagement; required for ADCs where Fc activation would produce systemic inflammatory toxicity
Early ADC developers defaulted to IgG4 subclass for Fc silencing due to its naturally weak FcγR binding. However, IgG4 undergoes Fab-arm exchange in vivo — half-antibodies swap between IgG4 molecules, generating bispecific hybrids with unpredictable target engagement. Engineered IgG1 with LALA or LALA-PG mutations is now the industry standard for Fc-silent ADCs, and these specific mutation combinations are themselves subject to licensing considerations.
The Seagen v. Daiichi Sankyo Case: A Defining Moment for ADC Patent Scope
No single case has shaped ADC patent strategy more consequentially in the past decade than Seagen's litigation against Daiichi Sankyo over trastuzumab deruxtecan (Enhertu).
What Was at Stake
Seagen held foundational patents on peptide-based cleavable linkers — specifically valine-citrulline (vc) dipeptide and related sequences — that were central to the auristatin-based ADC platform (including Adcetris). The original claims covered peptide linkers containing 2–12 amino acids broadly. Continuation applications later narrowed the focus to tetrapeptide linkers, which Seagen argued read on the GGFG tetrapeptide linker in Enhertu's structure.
The Federal Circuit's Ruling
The US Court of Appeals for the Federal Circuit invalidated the asserted Seagen patents on written description and enablement grounds. The core finding: the original specification — written at a time when only a narrow set of peptide linker structures had been experimentally validated — could not support claims broad enough to encompass the full 2–12 amino acid range, nor continuation claims that attempted to capture tetrapeptide linkers not specifically disclosed.
The Seagen ruling's enduring lesson: Claim scope must be commensurate with what the specification actually discloses and enables. In ADC linker chemistry, where structural diversity is enormous, drafting broad functional claims without comprehensive experimental support is a litigation liability, not a portfolio asset. The ruling will influence how examiners and courts evaluate ADC platform claims for years.
Enhertu vs. Kadcyla: Differentiation Through Technology
The Seagen litigation also clarified the IP boundary between two HER2-targeting ADCs that compete directly in the clinic:
| Feature | Kadcyla (T-DM1) | Enhertu (T-DXd) |
|---|---|---|
| Antibody | Trastuzumab (same) | Trastuzumab (same) |
| Linker type | Non-cleavable thioether (MCC) | Cleavable tetrapeptide (GGFG) |
| Toxin | DM1 (maytansinoid) | DXd (camptothecin derivative) |
| Average DAR | ~3.5 (heterogeneous, lysine) | ~8 (homogeneous, site-specific) |
| Bystander effect | Minimal (DM1 membrane-impermeable) | Strong (DXd membrane-permeable) |
| Patent overlap | None — non-overlapping IP positions despite same antibody target | |
The same trastuzumab antibody anchors both products, but the linker-toxin differentiation produces non-overlapping patent portfolios — and, clinically, Enhertu's superior DAR and bystander effect have translated into efficacy advantages in HER2-low breast cancer populations not addressable by Kadcyla. This is the most instructive case study in the ADC field for how technological differentiation and IP differentiation reinforce each other.
Freedom-to-Operate: The Overlooked Prerequisite
ADC FTO analysis is the most underestimated operational requirement in the field. Three failure modes recur consistently:
- "We have our own patents, so we have FTO" — false. Owning a patent on your antibody component does not create FTO against a third party's linker platform patent. IP ownership and freedom to operate are legally independent.
- Jurisdiction mismatch — a patent expired in the US may still be in force in Germany or Japan, and ADC manufacturing often occurs in jurisdictions where the patent is valid even if the commercial market is elsewhere.
- Patent term extensions (PTEs) and Supplementary Protection Certificates (SPCs) — these mechanisms can extend ADC component patents beyond their nominal 20-year term. Importantly, SPCs in Europe apply only to the approved product as a single agent; an SPC on Kadcyla cannot be extended to cover a new ADC that uses DM1 in a different combination.
ADC Patent Strategy Checklist
| Stage | Key IP Action | Why It Matters |
|---|---|---|
| Candidate selection | FTO search across all three components (Ab, linker, toxin) | Identifies blocking patents before committing to a molecule |
| Lead optimization | File structure-based antibody claims with functional data | Supports EPO prosecution; avoids written description issues |
| Linker selection | Evaluate licensed vs. proprietary linker platforms | In-licensing cost vs. freedom-to-operate certainty tradeoff |
| IND / clinical entry | Confirm patent term and SPC/PTE status in target markets | Defines commercial exclusivity window for ROI modeling |
| Commercial launch | Monitor continuation filings from competitors | Seagen case: continuations can target your linker even years later |
Frequently Asked Questions
What is an antibody-drug conjugate (ADC) and how is it structured?
An antibody-drug conjugate (ADC) combines the tumor-targeting specificity of a monoclonal antibody with the cytotoxic potency of a small-molecule payload. The canonical molecular architecture is Antibody–Linker–Toxin (A-L-T): the antibody selectively binds a tumor-associated antigen, the linker controls drug release kinetics and plasma stability, and the toxin kills the targeted cell upon internalization. As of 2024, 15 ADCs are approved globally and over 260 are in clinical trials across oncology indications. The global ADC market was $7.6 billion in 2022 and is projected to reach $28.6 billion by 2033.
How are ADC patents structured across antibody, linker, and toxin components?
ADC patents are independently filed for each of the three major components as well as for combinations. A novel antibody alone — even combined with known linker and toxin — is sufficient to establish novelty for the entire molecule. Similarly, a novel linker platform can support broad claims covering all antibody-toxin combinations that use it, creating the most commercially durable IP position in the field. Toxin patents cover chemical structure, synthesis route, and class-level claims for new payload categories. The FTO risk profile of any ADC maps to at minimum three independent patent domains from potentially three different owners.
What is drug-to-antibody ratio (DAR) and why does it matter for ADC patents?
Drug-to-antibody ratio (DAR) is the average number of toxin molecules attached per antibody molecule. Optimal DAR is typically 2–4 for most platforms — too low and potency is insufficient; too high and the antibody becomes hydrophobic, reducing plasma half-life and increasing off-target toxicity. Conventional lysine conjugation produces heterogeneous DAR distributions (0–8+). Site-specific methods — engineered cysteines (thio-MAb), enzymatic conjugation via transglutaminase with N297Q mutation, or unnatural amino acid incorporation — produce homogeneous, defined DAR. Controlling DAR distribution is one of the most commercially valuable and actively contested IP territories in ADC development.
What is freedom-to-operate (FTO) in ADC development and why is it complex?
Freedom-to-operate (FTO) analysis determines whether a company can develop, manufacture, and commercialize an ADC without infringing valid third-party patents. ADC FTO is exceptionally complex because a single molecule spans at least three independently patentable domains — each potentially covered by overlapping patents from different owners in multiple jurisdictions. A company can hold its own antibody patent and still infringe a third party's linker platform patent. FTO analysis must account for patent geography, remaining term, SPC/PTE extensions, legal status, and claim scope. Resolution pathways include licensing, inter partes review (IPR) challenge in the US, EPO opposition, or design-around approaches.
What happened in the Seagen v. Daiichi Sankyo ADC patent case?
Seagen asserted patents broadly covering peptide-based cleavable linkers (2–12 amino acids) against Daiichi Sankyo's trastuzumab deruxtecan (Enhertu), using a GGFG tetrapeptide linker. Continuation applications narrowed Seagen's claims to tetrapeptide linkers specifically. The US Court of Appeals for the Federal Circuit invalidated the asserted patents on written description and enablement grounds — the original specification, written when only limited linker structures had been experimentally demonstrated, could not support claims broad enough to encompass all peptide linkers in the filed scope. The ruling established that in ADC linker chemistry, claim scope must match experimental disclosure — broad functional claims without comprehensive supporting data are an invalidity liability.
How do Enhertu and Kadcyla differ in their patent positions?
Both Kadcyla (trastuzumab emtansine) and Enhertu (trastuzumab deruxtecan) use trastuzumab as the antibody, but their linker-toxin components are entirely different and protected by non-overlapping patents. Kadcyla uses a non-cleavable MCC-DM1 maytansinoid with random lysine conjugation (DAR ~3.5). Enhertu uses a cleavable GGFG tetrapeptide linker with DXd topoisomerase inhibitor and site-specific conjugation (DAR ~8), producing a strong bystander effect through DXd membrane permeability. These technological differences — and their distinct patent footprints — result in non-overlapping IP positions despite targeting the same antigen, and underpin Enhertu's efficacy advantages in HER2-low tumors inaccessible to Kadcyla.
What antibody patent claim types are accepted in the US, Europe, and China for ADCs?
Structure-based claims (defined by CDR sequences, VH/VL domains, or full antibody sequence) are the universal standard accepted by the USPTO, EPO, and CNIPA. Target/epitope-based claims — defined only by what the antibody binds, without structural specification — are accepted by the EPO under specific conditions but rejected by both the USPTO and CNIPA. European prosecution requires experimental data demonstrating functional superiority over prior-art antibodies to the same target (superior kinetics, unique epitope, better thermostability), as the EPO considers generating another antibody against a known target to be routine practice under the problem-and-solution approach.
What Fc engineering strategies are used in ADCs and how are they covered by patents?
ADC Fc engineering addresses the ADCC trade-off: Fc-mediated killing contributes anti-tumor activity but also broadens toxicity and narrows the therapeutic window. ADCC-enhancing mutations (S239D/I332E; afucosylation via FUT8 knockout) are patented by Xencor and Roche. ADCC-silencing mutations — L234A/L235A (LALA) and L234A/L235A/P329G (LALA-PG) — are covered by patents held by multiple parties and are now subject to in-licensing in several ADC development programs. IgG4 subclass, an earlier approach to Fc silencing, carries in vivo Fab-arm exchange liability and has been largely superseded by engineered IgG1 variants. Each set of Fc mutations represents its own patent consideration in an ADC development plan.
Sekbio's recombinant antibody development platform supports ADC antibody component engineering — from sequence optimization and site-specific cysteine introduction to CHO stable cell line establishment for homogeneous conjugation-ready antibody supply.
Developing an ADC Antibody Component or Need Conjugation-Ready Antibody Supply?
Sekbio's antibody engineering team supports ADC programs with site-specific engineering, CHO-expressed antibody production, and analytical characterization — including SPR kinetics, SEC-HPLC, and charge variant profiling to support both technical and IP documentation requirements.
Discuss Your ADC Project View Antibody Engineering Services